With the funding, Zerigo Health aims to reach a greater number of the 40M Americans living with psoriasis, vitiligo, and eczema. Here are the top-line bullets you need to know.
Zerigo Health, a telehealth startup, has raised $43M in a Series B. The round drew participation from 7wire Ventures, Cigna Ventures, Leaps by Bayer, General Catalyst, Leverage Health, Bluestem Capital Partners, and Dragoneer Investment Group, among others.
HOW’S THE COMPANY PERFORMING?
- San Diego-based Zerigo Health offers natural light therapy for eczema, psoriasis, and vitiligo.
- The company uses a combination of smart technology and coaching to administer treatments.
- Patients can self-administer the UVB light therapy treatment using the company’s proprietary hand-held medical device and a cell phone.
- Zerigo Health operates in the US.
Source: Zerigo Health
WHY DOES THE MARKET MATTER?
- The global light therapy market is expected to grow at a CAGR of 5.1% and reach a value of $1.3B by 2027, according to Global Market Insights.
- The rising prevalence of skin conditions and demand for non-invasive therapies are driving market growth.
- The demand for telehealth solutions has risen dramatically amid Covid-19, as they facilitate remote care.
